Brokerages Expect Tetraphase Pharmaceuticals Inc (TTPH) to Post -$0.34 Earnings Per Share

Wall Street analysts expect Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) to post earnings of ($0.34) per share for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Tetraphase Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.28) and the lowest estimate coming in at ($0.40). Tetraphase Pharmaceuticals reported earnings of ($0.63) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 46%. The business is expected to issue its next quarterly earnings results on Thursday, November 1st.

On average, analysts expect that Tetraphase Pharmaceuticals will report full-year earnings of ($1.38) per share for the current year, with EPS estimates ranging from ($1.82) to ($1.05). For the next fiscal year, analysts anticipate that the business will report earnings of ($1.14) per share, with EPS estimates ranging from ($1.77) to ($0.77). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research firms that that provide coverage for Tetraphase Pharmaceuticals.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last announced its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($0.18) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.36) by $0.18. Tetraphase Pharmaceuticals had a negative return on equity of 67.34% and a negative net margin of 421.64%. The business had revenue of $11.58 million during the quarter, compared to the consensus estimate of $2.23 million.

A number of brokerages recently issued reports on TTPH. ValuEngine raised Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, June 2nd. Needham & Company LLC reaffirmed a “hold” rating on shares of Tetraphase Pharmaceuticals in a report on Friday, August 3rd. B. Riley upped their price target on Tetraphase Pharmaceuticals from $6.00 to $7.00 and gave the company a “buy” rating in a report on Tuesday, August 28th. Zacks Investment Research raised Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.25 price target for the company in a report on Thursday, August 2nd. Finally, HC Wainwright upped their price target on Tetraphase Pharmaceuticals from $6.00 to $7.00 and gave the company a “buy” rating in a report on Tuesday, August 28th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and seven have assigned a buy rating to the company. Tetraphase Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $6.41.

Shares of TTPH opened at $3.14 on Friday. The company has a market capitalization of $170.21 million, a P/E ratio of -1.19 and a beta of 2.65. Tetraphase Pharmaceuticals has a 52-week low of $2.05 and a 52-week high of $7.98.

Several hedge funds have recently bought and sold shares of TTPH. Flagship Harbor Advisors LLC acquired a new stake in shares of Tetraphase Pharmaceuticals in the second quarter valued at approximately $104,000. Cubist Systematic Strategies LLC boosted its holdings in shares of Tetraphase Pharmaceuticals by 232.1% in the second quarter. Cubist Systematic Strategies LLC now owns 35,537 shares of the biopharmaceutical company’s stock valued at $127,000 after acquiring an additional 24,837 shares during the period. Canada Pension Plan Investment Board acquired a new stake in shares of Tetraphase Pharmaceuticals in the second quarter valued at approximately $179,000. Dynamic Technology Lab Private Ltd boosted its holdings in shares of Tetraphase Pharmaceuticals by 322.1% in the first quarter. Dynamic Technology Lab Private Ltd now owns 76,108 shares of the biopharmaceutical company’s stock valued at $234,000 after acquiring an additional 58,079 shares during the period. Finally, Alambic Investment Management L.P. acquired a new stake in shares of Tetraphase Pharmaceuticals in the first quarter valued at approximately $356,000. 40.94% of the stock is owned by institutional investors and hedge funds.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

Featured Story: Tariff

Get a free copy of the Zacks research report on Tetraphase Pharmaceuticals (TTPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply